Zhu M, Chen H, Chen X, Zhang Y, Chen X, Zhou B
Pharmaceutics. 2025; 17(2).
PMID: 40006507
PMC: 11859493.
DOI: 10.3390/pharmaceutics17020139.
Cheng W, Lin P
Mol Biotechnol. 2025; .
PMID: 39992486
DOI: 10.1007/s12033-025-01404-w.
Xie L, Gan F, Hu Y, Zheng Y, Lan J, Liu Y
J Funct Biomater. 2025; 16(1).
PMID: 39852571
PMC: 11766108.
DOI: 10.3390/jfb16010015.
Hosseingholi Nouri S, Nitturi V, Ledbetter E, English C, Lau S, Klisch T
Cancers (Basel). 2025; 17(1.
PMID: 39796693
PMC: 11720051.
DOI: 10.3390/cancers17010064.
Li Y, Xu Z, Qi Z, Huang X, Li M, Liu S
Int J Nanomedicine. 2024; 19:10899-10915.
PMID: 39479174
PMC: 11524014.
DOI: 10.2147/IJN.S480799.
Genetic predisposition to myelodysplastic syndrome: Genetic counseling and transplant implications.
Liu Y, Calzone K, McReynolds L
Semin Hematol. 2024; 61(6):370-378.
PMID: 39443230
PMC: 11661499.
DOI: 10.1053/j.seminhematol.2024.09.003.
Recent Advances and Prospects of Nucleic Acid Therapeutics for Anti-Cancer Therapy.
Lee M, Lee M, Song Y, Kim S, Park N
Molecules. 2024; 29(19).
PMID: 39407665
PMC: 11477775.
DOI: 10.3390/molecules29194737.
Recent development of nanomaterials-based PDT to improve immunogenic cell death.
Tul Ain Q
Photochem Photobiol Sci. 2024; 23(10):1983-1998.
PMID: 39320675
DOI: 10.1007/s43630-024-00638-y.
Nanoparticle-mediated gene delivery of TRAIL to resistant cancer cells: A review.
Habibizadeh M, Lotfollahzadeh S, Mahdavi P, Mohammadi S, Tavallaei O
Heliyon. 2024; 10(16):e36057.
PMID: 39247341
PMC: 11379606.
DOI: 10.1016/j.heliyon.2024.e36057.
Advances in nucleic acid therapeutics: structures, delivery systems, and future perspectives in cancer treatment.
Zhang L, Lou W, Wang J
Clin Exp Med. 2024; 24(1):200.
PMID: 39196428
PMC: 11358240.
DOI: 10.1007/s10238-024-01463-4.
Cytotoxic Potential of Betulinic Acid Fatty Esters and Their Liposomal Formulations: Targeting Breast, Colon, and Lung Cancer Cell Lines.
Milan A, Mioc M, Mioc A, Gogulescu A, Mardale G, Avram S
Molecules. 2024; 29(14).
PMID: 39064977
PMC: 11279467.
DOI: 10.3390/molecules29143399.
M1-polarized macrophage-derived cellular nanovesicle-coated lipid nanoparticles for enhanced cancer treatment through hybridization of gene therapy and cancer immunotherapy.
Shin H, Han J, Shin S, Bae G, Son B, Kim T
Acta Pharm Sin B. 2024; 14(7):3169-3183.
PMID: 39027257
PMC: 11252390.
DOI: 10.1016/j.apsb.2024.03.004.
The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies.
Yu P, Zhu C, You X, Gu W, Wang X, Wang Y
Cell Death Dis. 2024; 15(6):433.
PMID: 38898003
PMC: 11186852.
DOI: 10.1038/s41419-024-06837-w.
Advances and challenges in gene therapy strategies for pediatric cancer: a comprehensive update.
Moaveni A, Amiri M, Shademan B, Farhadi A, Behroozi J, Nourazarian A
Front Mol Biosci. 2024; 11:1382190.
PMID: 38836106
PMC: 11149429.
DOI: 10.3389/fmolb.2024.1382190.
Acetone extracts of Berberis and L. induce apoptosis in MCF-7 breast cancer cells.
Uslu B, Yaman M, Ozdemir Sanci T, Gungormus M, Kopru C, Gunes F
Turk J Med Sci. 2024; 53(5):1476-1488.
PMID: 38813021
PMC: 10763770.
DOI: 10.55730/1300-0144.5715.
From standard therapies to monoclonal antibodies and immune checkpoint inhibitors - an update for reconstructive surgeons on common oncological cases.
Knoedler L, Huelsboemer L, Hollmann K, Alfertshofer M, Herfeld K, Hosseini H
Front Immunol. 2024; 15():1276306.
PMID: 38715609
PMC: 11074450.
DOI: 10.3389/fimmu.2024.1276306.
CRISPR editing to mimic porphyria combined with light: A new preclinical approach for prostate cancer.
Boutin J, Genevois C, Couillaud F, Lamrissi-Garcia I, Guyonnet-Duperat V, Bibeyran A
Mol Ther Oncol. 2024; 32(1):200772.
PMID: 38596305
PMC: 10899051.
DOI: 10.1016/j.omton.2024.200772.
How Precise are Nanomedicines in Overcoming the Blood-Brain Barrier? A Comprehensive Review of the Literature.
Mohapatra P, Gopikrishnan M, C G, Chandrasekaran N
Int J Nanomedicine. 2024; 19:2441-2467.
PMID: 38482521
PMC: 10932758.
DOI: 10.2147/IJN.S442520.
Extracellular Vesicles: A New Star for Gene Drug Delivery.
Sun M, Zhang H, Liu J, Chen J, Cui Y, Wang S
Int J Nanomedicine. 2024; 19:2241-2264.
PMID: 38465204
PMC: 10924919.
DOI: 10.2147/IJN.S446224.
Quinazolin-4-one/3-cyanopyridin-2-one Hybrids as Dual Inhibitors of EGFR and BRAF: Design, Synthesis, and Antiproliferative Activity.
Al-Wahaibi L, Hisham M, Abou-Zied H, Hassan H, Youssif B, Brase S
Pharmaceuticals (Basel). 2023; 16(11).
PMID: 38004388
PMC: 10674657.
DOI: 10.3390/ph16111522.